CClinicalTrials.gg
CompletedNCT03254550Updated Jul 11, 2019

PrEP Demonstration Study in Swaziland

An interventional study of PrEP Promotion Package in HIV Negative People Identified at Substantial Risk for HIV Infection, sponsored by Clinton Health Access Initiative Inc.. Completed at 6 sites in Swaziland. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-11.

Sponsored by Clinton Health Access Initiative Inc. · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
517
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

This stepped-wedge cluster-randomized trial is embedded in an 18-month observational cohort study that has the aim to assess the operationalization of oral Pre-Exposure Prophylaxis (PrEP) in Swaziland as an additional HIV combination prevention method among individuals at high risk of HIV infection. The trial aims to determine the effect of a healthcare facility-based PrEP promotion package on the number of clients who take up PrEP.

Read the detailed description

The study will assess who will be reached with an introduction to and an offer of PrEP - and who will take up PrEP - when PrEP becomes available through different delivery points in the public-sector health system, including outpatient department (OPD), antenatal care (ANC), postnatal care (PNC) , family planning (FP) , and following HIV counseling and testing (VCT).

In addition to PrEP reach and PrEP uptake, the study aims to establish PrEP retention and average costs per client, by different health systems delivery points and to assess the effectiveness of a feasible and low-cost PrEP Promotion Package (PPP). The exact composition of PPP will be informed by findings from in-depth- interviews with clients, providers, and PrEP stakeholders. The effect of the PPP on the monthly number of clients who are initiated on PrEP will be studied using a stepped-wedge cluster-randomized design. Specifically, the trial will have two sequences with three healthcare facilities in each sequence, and three periods. In the first period, all healthcare facilities will be in the control phase; in the second period three healthcare facilities will implement the PPP; and in the third period all six healthcare facilities will implement the PPP.

02

Conditions studied

  • HIV Negative People Identified at Substantial Risk for HIV Infection

Browse trials for

Keywords

  • PrEP
03

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Confirmed HIV negative by rapid antibody test following the National HIV testing services (HTS) algorithm on the day of PrEP initiation
  • > 16 years of age
  • Willing and able to provide written informed consent
  • Identified at substantial risk of acquiring HIV infection
  • No current or recent illness (within past month) consistent with acute HIV infection in combination with a preceding high risk exposure for HIV
  • No contraindications to the use of Tenofovir(TDF)/Lamivudine (3TC)
  • Ready to adhere to PrEP and willing to attend the follow up evaluations including repeat HIV testing and monitoring for side-effects

Exclusion criteria

Exclusion Criteria:

  • Younger than 16 years of age
  • Currently having symptoms of acute HIV infection
  • Suspicion of window period following a potential exposure to HIV
  • Body weight \< 40 kg
  • Creatinine clearance \<60 ml/min
  • Using other nephrotoxic drugs (e.g. aminoglycosides)
  • Not willing to come for follow up visits every 3 months which will include HIV testing and counselling and monitoring for side-effects.
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
517 participants (actual)

Study arms

  • No intervention
    Control phase

    This is the provision of PrEP without the use of the PrEP Promotion Package. PrEP promotion in the control phase consists of each clinic displaying posters that advertise PrEP, pamphlets, and palm cards that patients can take home from the clinic.

  • Experimental
    Intervention phase

    This is the provision of PrEP as in the control phase plus the addition of five PrEP promotion components, which constitute the PrEP Promotion Package (PPP). These five additions are: 1) a PrEP promotion video to be played in the waiting room, 2) T-shirts advertising PrEP to be worn by healthcare workers, iii) a flipchart to support healthcare workers' PrEP counseling, iv) an informational booklet for clients to take home, and v) self-risk assessment forms to be displayed in the waiting room.

    Other: PrEP Promotion Package

Interventions

  • OtherPrEP Promotion Package

    A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge

05

What researchers measure

Primary outcomes

  1. Uptake

    The monthly number of clients who was initiated on PrEP

    Time frame: 18 months

Secondary outcomes

  1. Risk assessment

    The monthly number of clients who underwent a risk assessment for PrEP eligibility

    Time frame: 18 months

  2. Substantial risk

    The monthly number of clients who was identified as being at a substantial risk of acquiring HIV

    Time frame: 18 months

  3. Acceptance conditional on risk

    % of HIV-negative clients at substantial risk for HIV infection who accepted a PrEP offer

    Time frame: 18 months

  4. Linkage

    The monthly number of clients who either took up PrEP or were linked to antiretroviral therapy

    Time frame: 12 months

  5. Retention at 6 months

    % of clients taking PrEP who were retained at six months after PrEP initiation. Retention was defined as attending all follow-up visits during the first 180 days after PrEP initiation not more than seven days after the scheduled appointment.

    Time frame: 6 months

  6. HIV incidence

    % of clients initiated on PrEP who seroconverted during the first six months after taking up PrEP.

    Time frame: 18 month

06

Study locations

6 sites
  • Hhukwini Clinic
    Hhukwini, Hhohho Region, Swaziland
  • Horo Clini
    Horo, Hhohho Region, Swaziland
  • Ndzingeni Nazarene Clinic
    Ndzingeni, Hhohho Region, Swaziland
  • Nfontjeni Clinic
    Nfontjeni, Hhohho Region, Swaziland
  • Siphocosini Clinic
    Siphocosini, Hhohho Region, Swaziland
  • Ndvwabangeni Nazarene Clinic
    Ndvwabangeni, Hhohho, Swaziland
07

References and documents

Study documents

  • Statistical analysis plan · Dec 19, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03254550
Lead sponsor
Clinton Health Access Initiative Inc.
Collaborators
Ministry of Health, Swaziland, Heidelberg University, Mylan Laboratories, World Health Organization
Responsible party
Sponsor
First posted
Aug 18, 2017
Start date
Aug 1, 2017
Primary completion
Jan 31, 2019
Completion
Mar 2, 2019
Last update
Jul 11, 2019

Study contacts

Sindy Matse, MPH
principal investigator · Eswatini National AIDS Program

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion